CIK 0001549595
- Large accelerated filer
Nurix Therapeutics, Inc.
Sign in to watch- Ticker
- NRIX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Nov 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 270838048
- Phone
- +1 415-660-5320
- Business address
- 1600 SIERRA POINT PKWY, BRISBANE, CA, 94005
- Former names
- Nurix, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,712,859
- in 10 filings, $1.0M under 10b5-1 plans
Net −$1,712,859. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 50 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-01-30 | Hansen Gwenn Chief Scientific Officer | Sale | −1,412 | $11.78 | $17K | 23,009 |
| 2023-01-30 | Hansen Gwenn Chief Scientific Officer | Option exercise · Restricted Stock Units | −3,207 | 38,481 | ||
| 2022-10-31 | van Houte Hans Chief Financial Officer | Sale | −739 | $12.88 | $10K | 74,803 |
| 2022-10-31 | Ring Christine General Counsel | Sale | −699 | $12.88 | $9K | 6,185 |
| 2022-10-31 | Hansen Gwenn Chief Scientific Officer | Sale | −1,165 | $12.88 | $15K | 21,214 |
| 2022-10-31 | Wolff Stefani EVP and COO | Sale | −350 | $12.88 | $5K | 3,402 |
| 2022-10-30 | van Houte Hans Chief Financial Officer | Option exercise | +2,886 | 75,542 | ||
| 2022-10-30 | van Houte Hans Chief Financial Officer | Option exercise · Restricted Stock Units | −2,886 | 37,519 | ||
| 2022-10-30 | Ring Christine General Counsel | Option exercise | +1,924 | 6,884 | ||
| 2022-10-30 | Ring Christine General Counsel | Option exercise · Restricted Stock Units | −1,924 | 25,013 | ||
| 2022-10-30 | Hansen Gwenn Chief Scientific Officer | Option exercise | +3,207 | 22,379 | ||
| 2022-10-30 | Hansen Gwenn Chief Scientific Officer | Option exercise · Restricted Stock Units | −3,207 | 41,688 | ||
| 2022-10-30 | Wolff Stefani EVP and COO | Option exercise | +962 | 3,752 | ||
| 2022-10-30 | Wolff Stefani EVP and COO | Option exercise · Restricted Stock Units | −962 | 12,506 | ||
| 2022-09-12 | Saltzman Edward C Director | Grant or award · Director Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2022-08-09 | Ring Christine General Counsel | Grant or award · Employee Stock Option (right to buy) | +40,199 | 40,199 | ||
| 2022-08-09 | Wolff Stefani EVP and COO | Grant or award · Employee Stock Option (right to buy) | +110,375 | 110,375 | ||
| 2022-08-09 | van Houte Hans Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +120,000 | 120,000 | ||
| 2022-08-09 | SANDS ARTHUR T President, CEO | Grant or award · Employee Stock Option (right to buy) | +400,000 | 400,000 | ||
| 2022-08-09 | Hansen Gwenn Chief Scientific Officer | Grant or award · Employee Stock Option (right to buy) | +60,298 | 60,298 |
Page 27 of 32 · 632 trades